Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

PURPOSE: The AVAglio (Avastin in Glioblastoma) and RTOG-0825 randomized, placebo-controlled phase III trials in newly diagnosed glioblastoma reported prolonged progression-free survival (PFS), but not overall survival (OS), with the addition of bevacizumab to radiotherapy plus temozolomide. To estab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Sandmann, Thomas, Bourgon, Richard, Garcia, Josep, Li, Congfen, Cloughesy, Timothy, Chinot, Olivier L., Wick, Wolfgang, Nishikawa, Ryo, Mason, Warren, Henriksson, Roger, Saran, Frank, Lai, Albert, Moore, Nicola, Kharbanda, Samir, Peale, Franklin, Hegde, Priti, Abrey, Lauren E., Phillips, Heidi S., Bais, Carlos
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5015426/
https://ncbi.nlm.nih.gov/pubmed/26124478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.5005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados